Azenta, Inc. (AZTA) Stock: Price, Forecast & Analyst Target
Azenta, Inc. (AZTA) — MoonshotScore 64/100 (Fair band), calculated Nov 18, 2026. Price $47.09 (-3.29%), as of the Nov 19, 2026 trading session; market cap $1.97B.
Educational signal · not a buy or sell recommendation · How to read this
Azenta, Inc. · AZTA · NASDAQ
Azenta, Inc. provides life science sample exploration and management solutions globally. The company operates through two segments: Life Sciences Products and Life Sciences Services, catering to pharmaceutical, biotech, and research institutions.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Azenta (AZTA)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Stalling growth and a full valuation, though quality is only middling; the market is already moving on it. Business Quality: Average; Financial Safety: Sound; Valuation: Full; Growth Durability: Shrinking; Momentum: Surging.
- EPS beat 1 of the last 3 reports
- Altman Z 5.36 · Piotroski F 5
- ROE -10.1% · ROA -0.7% · current ratio 2.67
Holding back: soft growth
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 65 | Fair | |
| 64 | Fair | |
| 65 | Fair | |
| 65 | Fair | |
| 64 | Fair | |
| 64 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $47.09 | |
| Change on the day | -3.29% | |
| 52-week range | $15.93 – $50.06 | |
| Market capitalisation | $1.97B | — |
| Shares traded on the day | 1.37M |
Price & events
Other perspectives
Council score for Azenta (AZTA): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company less favourably than the MoonshotScore does: Simons-style lens, Klarman-style lens and Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Azenta (AZTA), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Azenta, Inc. (AZTA) is listed on NASDAQ. It employs 2,900 people and is led by Martin D. Madaus. The market values it at $1.97B.
What do the latest results show for Azenta (AZTA)?
Short answer · as of
Against analyst estimates the company has EPS beat 1 of the last 3 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Jun 2025 | $144M | -$48M | — |
| Sep 2025 | $159M | $51M | $1.11 (diluted) |
| Q1 FY2026 | $149M | -$15M | -$0.34 (diluted) |
| Q2 FY2026 | $145M | -$161M | -$3.49 (diluted) |
What are the financial strengths and risks for Azenta (AZTA)?
Short answer
The MoonshotScore pillars rate positive momentum as strengths. What is holding it back is soft growth. The distress and quality screens read Altman Z 5.36 · Piotroski F 5. Trailing ratios: ROE -10.1% · ROA -0.7% · current ratio 2.67.
What should you watch next at Azenta (AZTA)?
Short answer · as of
Current published price targets run low $52.00 · high $52.00 · consensus $52.00 · median $52.00 against a quoted price of $47.09 (as of Nov 19, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Azenta compare with its peers?
Short answer
Azenta's score ranks 8th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $55.45 Nov 18, 2026 | $2.82B | 95 5-pillar Nov 18, 2026 | |
| $75.58 Nov 18, 2026 | $1.73B | 88 5-pillar Nov 18, 2026 | |
| $120.37 Nov 19, 2026 | $5.48B | 83 5-pillar Nov 18, 2026 | |
| $84.41 Nov 19, 2026 | $5.06B | 81 5-pillar Nov 18, 2026 | |
| $25.03 Nov 19, 2026 | $1.26B | 80 5-pillar Nov 18, 2026 | |
| $15.93 Nov 19, 2026 | $4.35B | 73 5-pillar Nov 18, 2026 | |
| $175.76 Nov 19, 2026 | $4.40B | 73 5-pillar Nov 18, 2026 | |
| Azenta (AZTA) — this page | $47.09 | $1.97B | 64 |
| $24.13 Nov 19, 2026 | $3.00B | 62 5-pillar Nov 18, 2026 | |
| $163.40 Nov 19, 2026 | $6.48B | 61 5-pillar Nov 18, 2026 | |
| $8.49 Nov 19, 2026 | $1.69B | 31 5-pillar Nov 18, 2026 | |
| $45.83 Nov 18, 2026 | $3.37B | 27 5-pillar Nov 18, 2026 | |
| $97.63 Nov 19, 2026 | $9.27B | 26 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $52.00 – $52.00
- Consensus target
- $52.00
- Median target
- $52.00
Consensus record · Captured .
Measured against a quoted price of $47.09 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Oct 22, 2026
- Transactions
- 10
- Identified insiders
- 6
- Purchases
- 1
- Sales
- 0
- Other transactions
- 9
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held AZTA in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported AZTA in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Azenta (AZTA)?
- Azenta (AZTA) Stock Looks Reasonable With Sales Support In Place
- Azenta to Participate in the 9th Annual Evercore Healthcare Conference
- ROSEN, A LONGSTANDING LAW FIRM, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA
- What Azenta (AZTA) Said on Its Q4 Earnings Call
Common Questions About AZTA
These answers are editorial: 2 of these 9 answers are drawn from the AZTA research dossier (written May 10, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for AZTA?
AZTA carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Azenta, Inc. provides life science sample exploration and management solutions globally.
Is AZTA a good stock to buy?
Stock Expert AI does not rate AZTA buy, sell or hold. Azenta, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the AZTA stock price today?
The last price recorded for Azenta, Inc. (AZTA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the AZTA price target?
The analyst consensus price target for Azenta, Inc. (AZTA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What do analysts say about AZTA stock?
Analyst coverage of Azenta, Inc. is limited, but current sentiment suggests a cautious outlook. Key valuation metrics, such as price-to-earnings ratio, are not applicable due to the company's negative profit margin.
What are the key growth opportunities for AZTA in healthcare?
Azenta, Inc. has several key growth opportunities within the healthcare sector. Expanding its services into emerging therapeutic areas like cell and gene therapy presents a significant avenue for growth.
What are the key factors to evaluate for AZTA?
Azenta, Inc. (AZTA) holds a MoonshotScore in the moderate range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Operates in two segments: Life Sciences Products and Life Sciences Services, providing a diversified revenue stream. Not financial advice.
How frequently does AZTA data refresh on this page?
AZTA's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven AZTA's recent stock price performance?
Azenta, Inc. (AZTA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive service offerings covering both products and services. See the News tab for the latest drivers. Past performance does not predict future results.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 10 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com